US 9,808,515 B2
Treatment of social anxiety disorder using botulinum toxin
Eric Finzi, Washington, DC (US); and Norman E. Rosenthal, Rockville, MD (US)
Filed by Eric Finzi, Washington, DC (US); and Norman E. Rosenthal, Rockville, MD (US)
Filed on Sep. 27, 2016, as Appl. No. 15/277,909.
Application 15/277,909 is a continuation of application No. 14/984,299, filed on Dec. 30, 2015, abandoned.
Application 14/984,299 is a continuation of application No. 14/538,503, filed on Nov. 11, 2014, granted, now 9,254,314, issued on Feb. 9, 2016.
Claims priority of provisional application 61/903,292, filed on Nov. 12, 2013.
Prior Publication US 2017/0014493 A1, Jan. 19, 2017
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/48 (2006.01); A61K 31/5513 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/4893 (2013.01) [A61K 31/5513 (2013.01); A61K 45/06 (2013.01); C12Y 304/24069 (2013.01)] 16 Claims
 
1. A method for treating a social anxiety disorder in a subject, comprising administering a therapeutically effective amount of a Botulinum toxin to a corrugator supercilii and/or a procerus muscle of the subject to cause paralysis of the corrugator supercilii and/or a procerus muscle, and optionally administering the Botulinum toxin to the depressor anguli oris muscles of the subject, thereby treating the social anxiety disorder in the subject, wherein the Botulinum toxin does not cross a blood-brain barrier in the subject.